Literature DB >> 9636198

Expression of the peroxisome proliferator-activated receptor gamma (PPARgamma) in human atherosclerosis and regulation in macrophages by colony stimulating factors and oxidized low density lipoprotein.

M Ricote1, J Huang, L Fajas, A Li, J Welch, J Najib, J L Witztum, J Auwerx, W Palinski, C K Glass.   

Abstract

The peroxisome proliferator-activated receptor gamma (PPARgamma) is a ligand-dependent transcription factor that has been demonstrated to regulate fat cell development and glucose homeostasis. PPARgamma is also expressed in a subset of macrophages and negatively regulates the expression of several proinflammatory genes in response to natural and synthetic ligands. We here demonstrate that PPARgamma is expressed in macrophage foam cells of human atherosclerotic lesions, in a pattern that is highly correlated with that of oxidation-specific epitopes. Oxidized low density lipoprotein (oxLDL) and macrophage colony-stimulating factor, which are known to be present in atherosclerotic lesions, stimulated PPARgamma expression in primary macrophages and monocytic cell lines. PPARgamma mRNA expression was also induced in primary macrophages and THP-1 monocytic leukemia cells by the phorbol ester 12-O-tetradecanoylphorbol 13-acetate (TPA). Inhibition of protein kinase C blocked the induction of PPARgamma expression by TPA, but not by oxLDL, suggesting that more than one signaling pathway regulates PPARgamma expression in macrophages. TPA induced the expression of PPARgamma in RAW 264.7 macrophages by increasing transcription from the PPARgamma1 and PPARgamma3 promoters. In concert, these observations provide insights into the regulation of PPARgamma expression in activated macrophages and raise the possibility that PPARgamma ligands may influence the progression of atherosclerosis.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9636198      PMCID: PMC22700          DOI: 10.1073/pnas.95.13.7614

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  42 in total

1.  The structure-activity relationship between peroxisome proliferator-activated receptor gamma agonism and the antihyperglycemic activity of thiazolidinediones.

Authors:  T M Willson; J E Cobb; D J Cowan; R W Wiethe; I D Correa; S R Prakash; K D Beck; L B Moore; S A Kliewer; J M Lehmann
Journal:  J Med Chem       Date:  1996-02-02       Impact factor: 7.446

2.  Lymphohematopoietic progenitors immortalized by a retroviral vector harboring a dominant-negative retinoic acid receptor can recapitulate lymphoid, myeloid, and erythroid development.

Authors:  S Tsai; S Bartelmez; E Sitnicka; S Collins
Journal:  Genes Dev       Date:  1994-12-01       Impact factor: 11.361

Review 3.  Structures and functions of multiligand lipoprotein receptors: macrophage scavenger receptors and LDL receptor-related protein (LRP).

Authors:  M Krieger; J Herz
Journal:  Annu Rev Biochem       Date:  1994       Impact factor: 23.643

4.  A prostaglandin J2 metabolite binds peroxisome proliferator-activated receptor gamma and promotes adipocyte differentiation.

Authors:  S A Kliewer; J M Lenhard; T M Willson; I Patel; D C Morris; J M Lehmann
Journal:  Cell       Date:  1995-12-01       Impact factor: 41.582

5.  15-Deoxy-delta 12, 14-prostaglandin J2 is a ligand for the adipocyte determination factor PPAR gamma.

Authors:  B M Forman; P Tontonoz; J Chen; R P Brun; B M Spiegelman; R M Evans
Journal:  Cell       Date:  1995-12-01       Impact factor: 41.582

6.  An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma).

Authors:  J M Lehmann; L B Moore; T A Smith-Oliver; W O Wilkison; T M Willson; S A Kliewer
Journal:  J Biol Chem       Date:  1995-06-02       Impact factor: 5.157

Review 7.  Atherosclerosis: basic mechanisms. Oxidation, inflammation, and genetics.

Authors:  J A Berliner; M Navab; A M Fogelman; J S Frank; L L Demer; P A Edwards; A D Watson; A J Lusis
Journal:  Circulation       Date:  1995-05-01       Impact factor: 29.690

8.  Isolation of the human peroxisome proliferator activated receptor gamma cDNA: expression in hematopoietic cells and chromosomal mapping.

Authors:  M E Greene; B Blumberg; O W McBride; H F Yi; K Kronquist; K Kwan; L Hsieh; G Greene; S D Nimer
Journal:  Gene Expr       Date:  1995

9.  Generation, characterization, and histochemical application of monoclonal antibodies selectively recognizing oxidatively modified apoB-containing serum lipoproteins.

Authors:  A Hammer; G Kager; G Dohr; H Rabl; I Ghassempur; G Jürgens
Journal:  Arterioscler Thromb Vasc Biol       Date:  1995-05       Impact factor: 8.311

Review 10.  The nuclear receptor superfamily: the second decade.

Authors:  D J Mangelsdorf; C Thummel; M Beato; P Herrlich; G Schütz; K Umesono; B Blumberg; P Kastner; M Mark; P Chambon; R M Evans
Journal:  Cell       Date:  1995-12-15       Impact factor: 41.582

View more
  163 in total

1.  IL-4 inhibits osteoclast formation through a direct action on osteoclast precursors via peroxisome proliferator-activated receptor gamma 1.

Authors:  A C Bendixen; N K Shevde; K M Dienger; T M Willson; C D Funk; J W Pike
Journal:  Proc Natl Acad Sci U S A       Date:  2001-02-20       Impact factor: 11.205

Review 2.  Peroxisome proliferator activated receptor gamma: a potential therapeutic target in the management of ischaemic heart disease.

Authors:  J S Sidhu; J C Kaski
Journal:  Heart       Date:  2001-09       Impact factor: 5.994

3.  Peroxisome proliferator-activated receptor gamma ligands and atherosclerosis: ending the heartache.

Authors:  E D Rosen; B M Spiegelman
Journal:  J Clin Invest       Date:  2000-09       Impact factor: 14.808

4.  PPARs and lipid ligands in inflammation and metabolism.

Authors:  Gregory S Harmon; Michael T Lam; Christopher K Glass
Journal:  Chem Rev       Date:  2011-10-12       Impact factor: 60.622

5.  Effects of the PPARG P12A and C161T gene variants on serum lipids in coronary heart disease patients with and without Type 2 diabetes.

Authors:  Hulya Yilmaz-Aydogan; Ozlem Kurnaz; Ozlem Kurt; Basak Akadam-Teker; Ozlem Kucukhuseyin; Atike Tekeli; Turgay Isbir
Journal:  Mol Cell Biochem       Date:  2011-07-21       Impact factor: 3.396

Review 6.  Control of macrophage activation and function by PPARs.

Authors:  Ajay Chawla
Journal:  Circ Res       Date:  2010-05-28       Impact factor: 17.367

7.  Macrophage-Associated Lipin-1 Enzymatic Activity Contributes to Modified Low-Density Lipoprotein-Induced Proinflammatory Signaling and Atherosclerosis.

Authors:  Aimee E Vozenilek; Aaron R Navratil; Jonette M Green; David T Coleman; Cassidy M R Blackburn; Alexandra C Finney; Brenna H Pearson; Roman Chrast; Brian N Finck; Ronald L Klein; A Wayne Orr; Matthew D Woolard
Journal:  Arterioscler Thromb Vasc Biol       Date:  2017-12-07       Impact factor: 8.311

8.  Differential inhibition of macrophage foam-cell formation and atherosclerosis in mice by PPARalpha, beta/delta, and gamma.

Authors:  Andrew C Li; Christoph J Binder; Alejandra Gutierrez; Kathleen K Brown; Christine R Plotkin; Jennifer W Pattison; Annabel F Valledor; Roger A Davis; Timothy M Willson; Joseph L Witztum; Wulf Palinski; Christopher K Glass
Journal:  J Clin Invest       Date:  2004-12       Impact factor: 14.808

9.  15-deoxy-Delta12,14-prostaglandin J2 (15d-PGJ2) and ciglitazone modulate Staphylococcus aureus-dependent astrocyte activation primarily through a PPAR-gamma-independent pathway.

Authors:  Nirmal K Phulwani; Douglas L Feinstein; Vitaliy Gavrilyuk; Candan Akar; Tammy Kielian
Journal:  J Neurochem       Date:  2006-12       Impact factor: 5.372

10.  Peroxisome proliferator-activated receptor-gamma regulates the expression of alveolar macrophage macrophage colony-stimulating factor.

Authors:  Tracey L Bonfield; Mary Jane Thomassen; Carol F Farver; Susamma Abraham; Mary T Koloze; Xia Zhang; David M Mosser; Daniel A Culver
Journal:  J Immunol       Date:  2008-07-01       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.